CO6220909A2 - Moduladores de cannabinoides hexahidro-cicloheptapirazol - Google Patents

Moduladores de cannabinoides hexahidro-cicloheptapirazol

Info

Publication number
CO6220909A2
CO6220909A2 CO09109472A CO09109472A CO6220909A2 CO 6220909 A2 CO6220909 A2 CO 6220909A2 CO 09109472 A CO09109472 A CO 09109472A CO 09109472 A CO09109472 A CO 09109472A CO 6220909 A2 CO6220909 A2 CO 6220909A2
Authority
CO
Colombia
Prior art keywords
positions
hydroxy
halogen
optionally substituted
alkyl
Prior art date
Application number
CO09109472A
Other languages
English (en)
Inventor
Mingde Xia
Huajun Lu
Fina Liotta
Meng Pang
Michael P Wachter
Mark J Macielag
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6220909A2 publication Critical patent/CO6220909A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

1.- Un compuesto que tiene una estructura de acuerdo a la fórmula (I):o una sal, isómero, profármaco, metabolito o polimorfo del mismo en donde las líneas de puntos entre las posiciones 2-3 y las posiciones 3a-8a en la fórmula (I) representan sitios para cada uno de los dos dobles enlaces presentes cuando X1R1 está presente; las líneas de puntos entre las posiciones 3-3a y las posiciones 8a-1 en la fórmula (I) representan sitios para cada uno de los dos enlaces dobles presentes cuando X2R2 está presente; la línea de puntos entre la posición 8 y X4R4 en la fórmula (I) representa el sitio para un enlace doble; X1 está ausente o es alquileno inferior; X2 está ausente o es alquileno inferior; en donde solamente uno de X1R2 y X2R2 está presente; X3 está ausente, alquileno inferior, alquilideno inferior o -NH-; cuando la línea de puntos entre la posición 8 y X4R4 está ausente, o es alquileno inferior; cuando la línea de puntos entre la posición 8 y X4R4 está presente, X4 está ausente; X5 está ausente o es alquileno inferior; R1 se selecciona de hidrógeno, alquilo (opcionalmente sustituido en una o más posiciones por halógeno, hidroxi o alcoxi inferior), alquil-sulfonilo inferior, arilo, cicloalquilo de C3-C12 o heterociclilo, en donde arilo, cicloalquilo de C3-C12 o heterociclilo es cada uno opcionalmente sustituido en una o más posiciones por halógeno, aminosulfonilo, alquil-aminosulfonilo inferior, alquilo (opcionalmente sustituido en una o más posiciones por halógeno, hidroxi o alcoxi inferior), hidroxi o alcoxi inferior (opcionalmente sustituido en una o más posiciones por halógeno o hidroxi; R2 se selecciona de hidrógeno, alquilo (opcionalmente sustituido en una o más posiciones por halógeno, hidroxi o alcoxi inferior), alquil-sulfonilo inferior, arilo, cicloalquilo de C3-C12 o heterociclilo, en donde arilo, cicloalquilo de C3-C12 o heterociclilo es cada uno opcionalmente sustituido en una o más posiciones por halógeno, aminosulfonilo, alquil-aminosulfonilo inferior, alquilo (opcionalmente sustituido en una o más posiciones por halógeno, hidroxi o alcoxi inferior), hidroxi o alcoxi inferior (opcionalmente sustituido en una o más posiciones por halógeno o hidroxi); R3 es -C(O)-Z1(R6), -SO2-NR7-Z2(R8) o -C(O)-NR9-Z3(R10); ...
CO09109472A 2007-03-20 2009-10-05 Moduladores de cannabinoides hexahidro-cicloheptapirazol CO6220909A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/688,552 US8378117B2 (en) 2005-09-23 2007-03-20 Hexahydro-cycloheptapyrazole cannabinoid modulators

Publications (1)

Publication Number Publication Date
CO6220909A2 true CO6220909A2 (es) 2010-11-19

Family

ID=39189452

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09109472A CO6220909A2 (es) 2007-03-20 2009-10-05 Moduladores de cannabinoides hexahidro-cicloheptapirazol

Country Status (18)

Country Link
US (1) US8378117B2 (es)
EP (1) EP2139328A4 (es)
JP (1) JP2010529949A (es)
KR (1) KR20100015602A (es)
CN (1) CN101677557A (es)
AR (1) AR065799A1 (es)
AU (1) AU2008229202A1 (es)
BR (1) BRPI0809037A2 (es)
CA (1) CA2681468A1 (es)
CL (1) CL2008000799A1 (es)
CO (1) CO6220909A2 (es)
IL (1) IL200957A0 (es)
MX (1) MX2009010157A (es)
NZ (1) NZ579649A (es)
PE (1) PE20090061A1 (es)
TW (1) TW200901976A (es)
UA (1) UA98487C2 (es)
WO (1) WO2008115705A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008229264A1 (en) * 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Method for treating CB2 receptor mediated pain
EP2391627B1 (en) * 2009-01-28 2013-12-25 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
WO2022132545A1 (en) * 2020-12-15 2022-06-23 Merck Sharp & Dohme Corp. Fused [7,5] bicyclic pyrazole derivatives and methods of use thereof for the treatment of herpesviruses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DK153787C (da) * 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5164381A (en) * 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US6083969A (en) * 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
FR2800372B1 (fr) 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
FR2800375B1 (fr) 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
WO2002026224A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7271189B2 (en) * 2003-10-20 2007-09-18 Solvay Pharmaceuticals, Inc. 1H-imidazole derivatives as cannabinoid receptor modulators
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US20080249154A1 (en) * 2003-12-26 2008-10-09 Ono Pharmaceutical Co., Ltd. Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
PL1735286T3 (pl) 2004-03-24 2012-06-29 Janssen Pharmaceutica Nv Tetrahydro-indazolowe modulatory kannabinoidowe
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
BRPI0616401A2 (pt) * 2005-09-23 2011-06-21 Janssen Pharmaceutica Nv moduladores de hexa-hidro-ciclo-otil pirazol canabinoide e uso dos mesmos
CA2623525A1 (en) * 2005-09-23 2007-04-05 Janssen Pharmaceutica N.V. Tetrahydro-indazolyl cannabinoid modulators
DK1937259T3 (da) * 2005-09-23 2012-02-13 Janssen Pharmaceutica Nv Hexahydro-cycloheptapyrazol-cannabinoid-modulatorer

Also Published As

Publication number Publication date
AR065799A1 (es) 2009-07-01
CL2008000799A1 (es) 2008-09-26
JP2010529949A (ja) 2010-09-02
TW200901976A (en) 2009-01-16
UA98487C2 (en) 2012-05-25
MX2009010157A (es) 2009-10-12
AU2008229202A1 (en) 2008-09-25
IL200957A0 (en) 2010-05-17
US20080070968A1 (en) 2008-03-20
CA2681468A1 (en) 2008-09-25
EP2139328A4 (en) 2010-07-07
NZ579649A (en) 2011-12-22
CN101677557A (zh) 2010-03-24
BRPI0809037A2 (pt) 2014-09-16
WO2008115705A3 (en) 2009-01-15
US8378117B2 (en) 2013-02-19
WO2008115705A2 (en) 2008-09-25
KR20100015602A (ko) 2010-02-12
EP2139328A2 (en) 2010-01-06
PE20090061A1 (es) 2009-01-26

Similar Documents

Publication Publication Date Title
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
CO6220909A2 (es) Moduladores de cannabinoides hexahidro-cicloheptapirazol
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
AR071385A1 (es) Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia.
AR105340A2 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
DOP2006000076A (es) Derivados de ciclopentapiridina y tetrahidroquinolina
CO6270259A2 (es) Novedosos compuestos derivados de amina unidos con alcoxifenilo
CO6270288A2 (es) Composicion fungicida que comprende cantidades significativamente efectivas de un derivadio de amida de acido carboxilico o su sal
CO6251287A2 (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato -842
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
ECSP088149A (es) 3-acilaminobenzanilidas insecticidas
AR092645A1 (es) Derivados biciclicos inhibidores de autotaxina (atx)
AR074304A1 (es) Moduladores heterociclicos de gamma- secretasa
CO6210825A2 (es) Derivado de heterocicliden-n-(aril)acetamina
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
CO6170405A2 (es) Composicion plaguicida que comprende fluopicolida y un compuesto insecticida
UY30009A1 (es) Compuestos benzoilpirazol y herbicidas que los contienen
PE20140968A1 (es) Derivados de benzamida sustituida
AR057197A1 (es) Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona
AR066603A1 (es) Derivados de arilamida pirimidona
CO6220932A2 (es) Moduladores de cannbinoides hexahidro-ciclooctil pirazol

Legal Events

Date Code Title Description
FC Application refused